Trials / Completed
CompletedNCT03645330
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)
Prospective Multicenter Observational Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic Non-small Cell Lung Cancer: (J-TAIL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,026 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, observational study is to assess the long-term effectiveness and safety of Atezolizumab in patients with advanced non-small cell lung cancer in clinical practice.
Detailed description
Primary endpoint: 18 months OS, Secondary endpoints: Overall Survival(OS), 12 months survival rate(12mo OS), 24 months survival rate(24mo OS), Progression-Free Survival(PFS), Time to treatment failure (TTF), Objective Response Rate(ORR), Disease Control Rate(DCR), Duration of Response(DOR) ,Safety and EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
Conditions
Timeline
- Start date
- 2018-08-15
- Primary completion
- 2021-07-08
- Completion
- 2021-07-08
- First posted
- 2018-08-24
- Last updated
- 2022-07-22
Locations
198 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03645330. Inclusion in this directory is not an endorsement.